Evidence-based care pathways create clearer routes to adoption

Tern plc

Evidence-based care pathways help healthcare systems make more consistent decisions across diagnosis, treatment and long-term disease management. They give clinicians a clearer framework for deciding what should happen, when it should happen and which factors should influence the next step.

Their value lies in reducing avoidable variation. Without a defined pathway, patients with similar conditions may receive different tests, referrals or treatments depending on where they are seen. A stronger pathway can support earlier action, clearer responsibilities and more efficient use of healthcare resources.

Diagnosis is often the first pressure point. Many conditions begin with symptoms that are difficult to distinguish from other illnesses. Delays can also arise from limited access to specialists, inconsistent referral processes and differences in local diagnostic capacity.

A well-designed pathway can reduce these risks by setting out when further investigation is needed and when specialist input should be sought. It can also help clinicians use patient-reported symptoms more effectively, especially where the impact on daily life is not fully captured by routine clinical measures.

Earlier diagnosis can improve the timing of treatment. In some conditions, this may reduce progression, limit complications and improve the patient’s long-term outlook. It can also reduce the cost and complexity created by repeated appointments, delayed referrals and unnecessary testing.

Treatment decisions are becoming more complex as the number of therapies increases. Clinicians must consider efficacy, safety, disease severity, previous treatment, comorbidities and patient preferences. In some cases, biomarker data and other diagnostic information also shape the decision.

Care pathways bring these factors together in a more structured way. They can define when treatment should begin, how it should be monitored and when it should be changed. This supports consistency while still allowing clinicians to adapt decisions to the individual patient.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

What HCPs say could reveal prescribing intent

Talking Medicines is using AI to analyse HCP conversations and identify the clinical and practical factors that may influence prescribing intent.

AI control of machines raises new security questions

AI is gaining the ability to control physical equipment, but establishing that machines are genuine, authorised and secure will be an important part of making this technology safe to deploy.

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Search